Maladies infectieuses dans les pays à ressources limitées – IDLIC

The team aims at maintaining a strong activity on HIV while reinforcing its research scope on several other infectious diseases. The team is currently composed of 21 researchers, 13 technicians/engineers and 12 doctoral/post-doctoral students. From 2009 to May 2014, the team published 278 papers.

Objectifs

The team has been working in partnership with African scientific partners for the past twenty years. It has a strong relationship with Côte d’Ivoire. Two platforms are available within the team: the international epidemiological database to evaluate AIDS (IeDEA) in West Africa (US NIH) and the French ANRS clinical trial unit for lower-income countries (MEREVA).

Coordonnées

Centre de recherche INSERM U1219
Université de Bordeaux – ISPED
146 rue Léo-Saignat
33076 BORDEAUX cedex

Tél : +33 (0)5 57 57 15 80
Tél : +33 (0)5 57 57 92 40
Tél : +33 (0)5 57 57 95 69



Informations

Axes

Current and future organization will be along two scientific axes: clinical research and epidemiological and public health research, applied to two broad themes, HIV and non-HIV.

  • The research on the HIV infections theme will be focusing on three priorities: early care, prevention of transmission and antiretroviral treatment (ART) strategies. Thus, the question “when to start ART“ in low resource countries (currently explored in Côte d’Ivoire) will shift to “when specifically not to start ART”. We will also move from the exploration of the universal test and treatment strategy in South Africa to the development of combination prevention approaches at population level in several African contexts. The development of HIV-2 treatment strategies will be a priority for West Africa.
  • The non-HIV theme will explore in priority HBV/HCV infections, infectious-related cancers and malaria and non-malarial febrile illnesses. How to make anti-HCV treatment as largely available as possible in Africa will be the first question addressed for viral hepatitis. Preventive strategies for human papilloma virus related cancers will be investigated. Finally the burden of malaria and spectrum of causes of non-malaria febrile illnesses will be studied in the rapidly evolving context of anti-malaria strategies.

 



Principales publications

  1. Becquet R, Bland R, Leroy V, Rollins NC, Ekouevi DK, Coutsoudis A, Dabis F, Coovadia HM, Salamon R, Newell ML. Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts. PLoS One. 2009 Oct 16;4(10):e7397
  2. Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d’Ivoire appraisal. PLoS Med. 2009 Oct;6(10):e1000173
  3. Anaky MF, Duvignac J, Wemin L, Kouakoussui A, Karcher S, Touré S, Seyler C, Fassinou P, Dabis F, N’Dri-Yoman T, Anglaret X, Leroy V. Scaling up antiretroviral therapy for HIV-infected children in Côte d’Ivoire: determinants of survival and loss to programme. Bull World Health Organ. 2010;88:490-9
  4. Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X. Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1-Infected Adults on Antiretroviral Therapy in Cote d’Ivoire. J Acquir Immune Defic Syndromes 2011;56:356-364
  5. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Menan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C. AIDS and Non-AIDS Morbidity and Mortality Across the Spectrum of CD4 Cell Counts in HIV-Infected Adults Before Starting ART in Cote d’Ivoire. Clin Infect Dis 2012;54:714-723

Membres


partenaires

logo_ISPED logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_HONcode